|
Jul 10
|
CRISPR Therapeutics (CRSP) Moves 9.6% Higher: Will This Strength Last?
|
|
Jul 9
|
CRISPR Therapeutics (NasdaqGM:CRSP) Advances Cardiovascular Programs With Promising Trial Results
|
|
Jul 9
|
Innovation ETF (ARKK) Hits New 52-Week High
|
|
Jul 9
|
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
|
|
Jul 7
|
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
|
|
Jul 3
|
H.C. Wainwright Reaffirms Buy Rating on CRISPR Therapeutics After CTX310 Update
|
|
Jun 30
|
Vertex Down Around 9% in Three Months: Should You Buy, Sell or Hold the Stock?
|
|
Jun 30
|
CRISPR Therapeutics Named to TIME’s Most Influential Companies List of 2025
|
|
Jun 27
|
Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?
|
|
Jun 26
|
CRISPR Therapeutics (NasdaqGM:CRSP) Announces Promising Data From Cardiovascular Disease Programs
|
|
Jun 26
|
CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline
|
|
Jun 25
|
CRISPR Therapeutics AG (CRSP) Stock Moves 1.88%: What You Should Know
|
|
Jun 25
|
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
|
|
Jun 24
|
CRISPR Therapeutics AG (CRSP) Surpasses Market Returns: Some Facts Worth Knowing
|
|
Jun 24
|
CRISPR Therapeutics AG (CRSP): A Bull Case Theory
|
|
Jun 24
|
Is CRISPR Therapeutics AG (NASDAQ:CRSP) Trading At A 45% Discount?
|
|
Jun 21
|
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
|
|
Jun 19
|
Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?
|
|
Jun 18
|
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
|
|
Jun 17
|
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
|